- November 14, 2016 from 12:00 PM to 1:30 PM
- Presented by: Richard Colonno, PhD, and Qi Huang, PhD, Director of Biology
- Summary: Assembly has developed a proprietary series of CpAM compounds that can both suppress viral replication and inhibit the formation of cccDNA in HBV cell infection assays. In comparison, nucleos(t)ide therapy, such as the the current HBV standard of care drug entecavir, can efficiently block viral replication but has only a modest impact on cccDNA levels.
INDIANAPOLIS, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biotherapeutics for disorders associated with the microbiome, today announced it will present new data at The Liver Meeting ® 2016, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held on November 11-15, 2016 in Boston. "This latest presentation shows that our proprietary core protein allosteric modulators (CpAMs) have unique antiviral properties, including the critical ability to stop the formation of new cccDNA," said Richard Colonno PhD, chief scientific officer of Assembly. "This data presentation is especially timely, as earlier this week we initiated the first Phase 1 trial of Assembly's lead CpAM candidate, ABI-H0731. We look forward to assessing the potential for CpAMs to help change the treatment paradigm and increase cure rates for HBV patients." Poster #1897:Blockage of HBV Virus Replication and Inhibition of cccDNA Establishment by Core Protein Allosteric Modifiers (CpAMs)